Global Sleep Medical Device Company Divests Non-Core Software to Accelerate Focus on Core Business

ResMed Inc. (NYSE: RMD) has signed a definitive agreement to sell its MatrixCare division—which provides software solutions to long-term care facilities, senior living communities, and home health agencies—to private equity firm Frazier Healthcare Partners. Through this divestiture, ResMed intends to redeploy capital and personnel into its high-growth core businesses of sleep and respiratory care and home-based connected healthcare. Subject to regulatory approvals and customary closing conditions, the transaction is expected to close in the first quarter of fiscal 2027, with additional financial impacts to be disclosed in the fiscal 2026 fourth-quarter filing. Until closing, MatrixCare will continue operating under its existing structure with no changes to customer service or support.

In the third quarter of fiscal 2026, ResMed reported revenue of $1.43 billion, an 11 percent increase year over year, alongside improved profitability and margins. The company is also reshaping its portfolio, agreeing to acquire medical device maker Noctrix Health for approximately $340 million to strengthen its position in the restless legs syndrome market.

ResMed is a global health-tech company that develops positive airway pressure devices (including CPAP and BiPAP), masks, and cloud-based monitoring software for patients with sleep apnea and chronic respiratory diseases. With a strong focus on home-based therapies and digital healthcare, ResMed is well positioned to benefit from long-term growth drivers such as aging populations, rising obesity rates, and the expansion of home care. The connected healthcare market—which encompasses sleep and respiratory therapy devices and remote monitoring solutions—is viewed as a key growth opportunity over the medium to long term.